
AlphaTON Capital Investor Relations Material
Latest events

Q4 2025
25 Jul, 2025

Q2 2025
25 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AlphaTON Capital Corp
Access all reports
Portage Biotech Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology treatments. The company is focused on advancing first-in-class therapies that target checkpoint resistance pathways, with the goal of achieving durable treatment responses and improving the quality of life for patients with cancer. Portage Biotech's approach aims to address the limitations of current cancer therapies by offering potentially more effective treatment options. The company's research and development efforts are concentrated on novel multi-targeted therapies that can be used both as monotherapies and in combination with other treatments to combat cancer more effectively. The company is headquartered in Westport, Connecticut, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ATON
Country
🇺🇸 United States